JP2022547885A5 - - Google Patents
Info
- Publication number
- JP2022547885A5 JP2022547885A5 JP2022514645A JP2022514645A JP2022547885A5 JP 2022547885 A5 JP2022547885 A5 JP 2022547885A5 JP 2022514645 A JP2022514645 A JP 2022514645A JP 2022514645 A JP2022514645 A JP 2022514645A JP 2022547885 A5 JP2022547885 A5 JP 2022547885A5
- Authority
- JP
- Japan
- Prior art keywords
- nutrin
- cdk4
- adenovirus
- inhibitor
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19000396.2 | 2019-09-05 | ||
| EP19000396 | 2019-09-05 | ||
| EP19000406.9 | 2019-09-12 | ||
| EP19000406 | 2019-09-12 | ||
| PCT/EP2020/074980 WO2021044061A1 (en) | 2019-09-05 | 2020-09-07 | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547885A JP2022547885A (ja) | 2022-11-16 |
| JP2022547885A5 true JP2022547885A5 (cg-RX-API-DMAC7.html) | 2023-09-15 |
| JP7834342B2 JP7834342B2 (ja) | 2026-03-24 |
Family
ID=72428285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514645A Active JP7834342B2 (ja) | 2019-09-05 | 2020-09-07 | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220354911A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025229A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7834342B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220079551A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114615996A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020342594A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3152965A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021044061A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4578943A4 (en) * | 2022-08-25 | 2026-02-25 | Fujifilm Corp | PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU2003242585A1 (en) | 2002-05-27 | 2003-12-12 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| WO2012022496A2 (en) * | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| SG11201507393TA (en) * | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| RU2670762C2 (ru) * | 2013-12-31 | 2018-10-25 | Хуаньчжу Фарма Ко., Лтд. | Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака |
| JP2017516862A (ja) * | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
| ES2899913T3 (es) * | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| CN107849111B (zh) * | 2015-05-04 | 2022-02-22 | Vcn生物科学有限公司 | 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途 |
| WO2018195202A1 (en) * | 2017-04-21 | 2018-10-25 | Pellficure Pharmaceuticals Inc. | Compositions and methods for the treatment of cancer |
| CA3066778A1 (en) * | 2017-06-21 | 2018-12-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| SG11202007873VA (en) * | 2018-03-05 | 2020-09-29 | Klinikum Rechts Der Isar Der Technischen Univ Muenchen | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
-
2020
- 2020-09-07 WO PCT/EP2020/074980 patent/WO2021044061A1/en not_active Ceased
- 2020-09-07 EP EP20768332.7A patent/EP4025229A1/en active Pending
- 2020-09-07 KR KR1020227011226A patent/KR20220079551A/ko active Pending
- 2020-09-07 CA CA3152965A patent/CA3152965A1/en active Pending
- 2020-09-07 AU AU2020342594A patent/AU2020342594A1/en active Pending
- 2020-09-07 US US17/640,720 patent/US20220354911A1/en active Pending
- 2020-09-07 CN CN202080070210.1A patent/CN114615996A/zh active Pending
- 2020-09-07 JP JP2022514645A patent/JP7834342B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | The roles of EZH2 in cancer and its inhibitors | |
| Phan et al. | P38 kinase in gastrointestinal cancers | |
| Qin et al. | Lenvatinib in hepatocellular carcinoma: resistance mechanisms and strategies for improved efficacy | |
| Zhuang et al. | The role of m6A methylation in therapy resistance in cancer | |
| Sofi et al. | Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications | |
| Tudor et al. | COX-2 as a potential biomarker and therapeutic target in melanoma | |
| Vilchez et al. | Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment | |
| Zandi et al. | Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance | |
| Hong et al. | LB100, a small molecule inhibitor of PP2A with potent chemo-and radio-sensitizing potential | |
| Ghorab et al. | New quinazoline sulfonamide derivatives as potential anticancer agents: Identifying a promising hit with dual EGFR/VEGFR-2 inhibitory and radiosensitizing activity | |
| Zhang et al. | HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET | |
| Lv et al. | Imperatorin induces autophagy and G0/G1 phase arrest via PTEN-PI3K-AKT-mTOR/p21 signaling pathway in human osteosarcoma cells in vitro and in vivo | |
| Mantwill et al. | Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents | |
| Li et al. | Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy | |
| Bryant et al. | Targeting hypoxia in the treatment of small cell lung cancer | |
| Shibahara et al. | TIP60 is required for tumorigenesis in non‐small cell lung cancer | |
| Miller et al. | Cyclin‐dependent kinases as therapeutic targets in melanoma | |
| Zheng et al. | Radiation-inducible protein RbAp48 contributes to radiosensitivity of cervical cancer cells | |
| Tong et al. | The emerging roles of histone demethylases in cancers | |
| Jiang et al. | Clinical applicability of renin-angiotensin system inhibitors in cancer treatment | |
| Yu et al. | DDX55 promotes hepatocellular carcinoma progression by interacting with BRD4 and participating in exosome‐mediated cell‐cell communication | |
| Kant et al. | Discovery of an orally efficacious MYC inhibitor for liver cancer using a GNMT-based high-throughput screening system and structure–activity relationship analysis | |
| JP2021517119A5 (cg-RX-API-DMAC7.html) | ||
| Saatloo et al. | Akt1 and Jak1 siRNA based silencing effects on the proliferation and apoptosis in head and neck squamous cell carcinoma | |
| Liu et al. | Small-molecule and peptide inhibitors of m6A regulators |